The invention belongs to the technical field of
biomedicine, and particularly relates to application of GABA (gamma-
aminobutyric acid) driven by
lactobacillus rhamnosus to treatment of
cerebral malaria of mice. According to the invention, the obviously enriched
lactobacillus muricatum is found, and the
lactobacillus muricatum is proved to be capable of generating GABA (gamma-
aminobutyric acid). Afterwards, on the mouse
cerebral malaria model, under the condition that the
lactobacillus rhamnosus and the GABA are independently used or auxiliary
dihydroartemisinin is used, the effect of the
lactobacillus rhamnosus and the GABA on improving and treating the mouse
cerebral malaria is evaluated. Results show that the strain and the
metabolite GABA thereof can effectively improve behavioristics of mice and immune
pathological injuries of all organs, reduce protozoemia and prolong the lifetime of the mice whether the strain is independently used or combined with
dihydroartemisinin, and can effectively treat cerebral
malaria of the mice compared with the strain which is independently used with drugs. The invention provides a brand-new solution for treating severe
malaria, especially
human brain malaria, caused by malignant malaria from the perspective that the probiotics drive metabolites of the probiotics to assist the anti-malarial
drug in treating
rat brain malaria.